Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (4125)	11/11/1999 9:29:00 AM
From: DanZ	Respond to of 19428

Infostream, I don't think that the number of shares outstanding will increase much over the next couple of quarters. The number of shares outstanding could go up due to the exercise of warrants, but I don't think it will exceed 8 to 8.5 million shares, if that much. The number of shares in Q3 was virtually unchanged. You're right about cold products being somewhat seasonal, but they don't drop to zero. Besides, when it is summer in the northern hemisphere, isn't it winter in the southern hemisphere? Also, people have told the company that Zicam helped alleviate their allergy symptoms. I did some research into this about a month ago to see if any connection might exist between nasal ICAM-1 and allergies. Lo and behold, I found quite a few articles on this subject. Here are two links. I have other links, but can't find them at the moment. record.wustl.edu munksgaard.dk There appears to be enough scientific evidence to reasonably hypothesize that an interaction exists between ICAM-1 and allergies. Zicam is known to interfere with the interaction of rhinoviruses with ICAM-1. The company has anecdotal evidence that Zicam alleviates allergy symptoms. Putting it all together, they are planning to conduct an independent clinical study to see if Zicam has any effect on allergies. The results should be published in time for the allergy season next spring. While more cold products are sold in the US in the winter months, if Zicam is effective against allergies, the ebb and flow due to seasonality will be less an issue. I haven't researched the population of the southern hemisphere or whether cough and cold products are popular there, but I wouldn't completely discount this as having no effect on the seasonality of sales without first doing some research. Regards, Dan